Dr Fabregas explains how ASCO 2025 showcased the major advancements in gastrointestinal cancer treatments.

The MATTERHORN trial demonstrates that adding durvalumab immunotherapy to standard care for gastric cancer enhances event-free survival and pathologic response rates.

The ATOMIC trial reports a 50% increase in disease-free survival for colorectal cancer patients treated with atezolizumab and chemotherapy.

The BREAKWATER trial indicates improved overall survival for patients with BRAF-mutated colorectal cancer (CRC), with future research focusing on immunotherapy to reduce treatment-related toxicities.